The Azer-cel and Vaxinia expansions are based on circumstantial evidence. Circumstantial evidence is a cornerstone of scientific progression. Like all things, evidence of this nature falls onto a spectrum from weak to strong. The cholangiocarcinoma data that preceded the expansion is an example of very weak circumstantial evidence because only a single patient responded, which naturally comes with greater risk. Evidence from over a thousand patients would be considered strong circumstantial evidence and comes with less risk. Investment in biotech is correlating clinical, commercial, and market risk to a commercial outcome.
Add to My Watchlist
What is My Watchlist?
